Dr. Chen is currently a Medical Officer in the Target Therapeutics 1 Section of the Investigational Drug Branch of the Cancer Therapy Evaluation Program of the National Cancer Institute. She is board certified in Internal Medicine and Medical Oncology. She has served as a primary and associate investigator in a broad spectrum of clinical trials ranging from phase 0 through phase 4. Her portfolio includes DNA binding agents and angiogenesis, integrin, HSP 90, PARP and topoisomerase inhibitors. Dr. Chen is also the CTEP contact for revision 4 of the Common Terminology Criteria for Adverse Events.
National Cancer Institute
Executive Plaza North, Suite 7128
Rockville MD, 20852-7426